Zobrazeno 1 - 10
of 102
pro vyhledávání: '"Cécile Borel"'
Autor:
Camille Gondran, Pierre-Yves Dumas, Emilie Bérard, Audrey Bidet, Eric Delabesse, Suzanne Tavitian, Thibaut Leguay, Françoise Huguet, Cécile Borel, Edouard Forcade, François Vergez, Jean-Philippe Vial, Jean Baptiste Rieu, Nicolas Lechevalier, Isabelle Luquet, Alban Canali, Emilie Klein, Audrey Sarry, Anne-Charlotte de Grande, Arnaud Pigneux, Christian Récher, Laetitia Largeaud, Sarah Bertoli
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Acute myeloid leukemia (AML) with t(9;22) (q34.1; q11.2)/BCR::ABL1, a distinct entity within the group of AML with defining genetic abnormalities, belong to the adverse-risk group of the 2022 ELN classification. However, there is little data
Externí odkaz:
https://doaj.org/article/4053055ddfc042fab15037068bcb7414
Autor:
Guillaume Beziat, Suzanne Tavitian, Francois-Xavier Arnaud, Françoise Izar, Justine Attal, Cécile Borel, Christian Recher, Anne Ducassou
Publikováno v:
Journal of Contemporary Brachytherapy, Vol 14, Iss 6, Pp 601-604 (2022)
Acute myeloid leukemia (AML) may extend to extra-medullary sites at diagnosis or at relapse, either isolated or associated with bone marrow disease. Granulocytic sarcoma of uterine cervix is rare, and there is no established treatment for this diseas
Externí odkaz:
https://doaj.org/article/a5330ccd3e294c3ebc6ab5deac3846b9
Autor:
Imran Ahmad, Laetitia Souchet, Fati Hamzy, Patrice Ceballos, Yohann Desbrosses, Aurélie Ravinet, Pascal Turlure, Alban Villate, Cécile Borel, Hanane Benbarkat, Ibrahim Yakoub-Agha, Thierry Guillaume
Publikováno v:
Bulletin du Cancer. 110:S56-S66
Autor:
Valérie Coiteux, Laurène Fenwarth, Nicolas Duployez, Malika Ainaoui, Cécile Borel, Alice Polomeni, Ibrahim Yakoub-Agha, Yves Chalandon
Publikováno v:
Bulletin du Cancer. 110:S13-S29
Autor:
Olivier Tournilhac, Magali Le Garff-Tavernier, Stéphanie Nguyen Quoc, Edouard Forcade, Patrice Chevallier, Faezeh Legrand-Izadifar, Gandhi Laurent Damaj, David Michonneau, Cécile Tomowiak, Cécile Borel, Corentin Orvain, Pascal Turlure, Rabah Redjou, Gaëlle Guillerm, Laure Vincent, Celestine Simand, Richard Lemal, Claire Quiney, Patricia Combes, Bruno Pereira, Laure Calvet, Aurélie Cabrespine, Jacques-Olivier Bay, Véronique Leblond, Nathalie Dhédin, French Innovative Leukemia Organization (FILO), Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
Publikováno v:
Haematologica, Vol 106, Iss 7 (2020)
Allogeneic hematopoietic stem cell transplantation (HSCT) remains a potentially curative and useful strategy in high-risk relapsing CLL. Minimal Residual Disease (MRD) assessment at 12 months post-HSCT is predictive of relapse. This phase 2 study aim
Externí odkaz:
https://doaj.org/article/513b282ddfd94a8f8cbad1c4cbd28f6d
Autor:
Aspasia Stamatoullas, Hervé Ghesquières, Pierre Feugier, Marc André, Fabien Le Bras, Anne-Claire Gac, Cécile Borel, Thomas Gastinne, Philippe Quittet, Franck Morschhauser, Vincent Ribrag, Stephanie Guidez, Emmanuelle Nicolas-Virelizier, Alina Berriolo-Riedinger, Thierry Vander Borght, Véronique Edeline, Pauline Brice
Publikováno v:
Leukemia & lymphoma, Vol. 63, no. 13, p. 3063-3071 (2022)
Leukemia & lymphoma
Leukemia & lymphoma, 2022, Leukemia & lymphoma, 63 (13), pp.3063-3071. ⟨10.1080/10428194.2022.2107204⟩
Leukemia & lymphoma
Leukemia & lymphoma, 2022, Leukemia & lymphoma, 63 (13), pp.3063-3071. ⟨10.1080/10428194.2022.2107204⟩
This phase I/II study assessed the combination of brentuximab vedotin (BV) with ifosfamide-carboplatin-etoposide (ICE) as a second-line therapy in refractory/relapsed (R/R) classical Hodgkin lymphoma (cHL) patients. Phase I study was designed to dete
Autor:
Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Hervé Avet-Loiseau, Jill Corre, Michel Attal
Publikováno v:
Blood, Vol. 139, no. 18, p. 2747-2757 (2022)
High-dose melphalan (HDM) and transplantation are recommended for eligible patients with multiple myeloma. No other conditioning regimen has proven to be more effective and/or safer. We previously reported in a phase 2 study that bortezomib can safel
Autor:
Nabil Yafour, Marie-Anne Couturier, Cécile Borel, Amandine Charbonnier, Tereza Coman, Amandine Fayard, Stavroula Masouridi-Levrat, Ibrahim Yakoub-Agha, Jean Roy
Publikováno v:
Bulletin du Cancer.
Autor:
Valérie, Coiteux, Laurène, Fenwarth, Nicolas, Duployez, Malika, Ainaoui, Cécile, Borel, Alice, Polomeni, Ibrahim, Yakoub-Agha, Yves, Chalandon
Publikováno v:
Bulletin du cancer.
The advent of new technologies has made it possible to identify genetic predispositions to myelodysplastic syndromes (MDS) and acute leukemias (AL) more frequently. The most frequent and best characterized at present are mutations in CEBPA, RUNX1, GA
Autor:
Marie-Therese Rubio, Roberta Di Blasi, Gilles Salles, Miguel A Perales, Kada Klouche, Muriel Picard, Pierre Sesques, Eric Mariotte, Michael Darmon, Boris Böll, Philippe R. Bauer, Sanjay Chawla, Kevin Rakszawski, Nahema Issa, Anne Huynh, Guillaume Cartron, Florence Rabian, Peter Borchmann, Michael Joannidis, Sabine Furst, Sophie de Guibert, Lara Zafrani, Patrice Ceballos, Nicolas Boissel, David Beauvais, Catherine Thieblemont, François-Xavier Gros, Alberto Mussetti, Gabriel Moreno-González, Adel Maamar, Florent Wallet, Faezeh Legrand, Julien Leroy, Quentin Quelven, Djamel Mokart, Valentin Ortiz, Christian Recher, Jakob Rudzki, Laura Platon, Pleun Hemelaar, Benoit Tessoulin, Reuben Benjamin, Sandrine Valade, Pedro Castro, Gennadii Galstian, Amélie Seguin, Peter Schellongowski, Anna Sureda, Alice Gallo De Moraes, Philipp Wohlfarth, Bruno Levy, Andry Van de Louw, Jorge Garcia Borrega, Julio Delgado, Ibrahim Yakoub-Agha, Nathalie Fégueux, Laveena Munshi, Yi Lin, Emmanuel Bachy, Stéphanie Harel, Sara Fernández, Bertrand Arnulf, Thomas Gastinne, Elie Azoulay, Didier Blaise, Amandine Le Bourgeois, Louis Voigt, Cécile Borel, Anne-Sophie Moreau, Christian Chabannon, Ulrich Jäger, Virginie Lemiale, Olga Gavrilina, Victoria Metaxa, Thomas Staudingert, Edouard Forcade
Publikováno v:
The Lancet Haematology
The Lancet Haematology, 2021, 8 (5), pp.e355-e364. ⟨10.1016/S2352-3026(21)00060-0⟩
The Lancet Haematology, Elsevier, 2021, 8 (5), pp.e355-e364. ⟨10.1016/S2352-3026(21)00060-0⟩
Lancet Haematology, 8, E355-E364
Dipòsit Digital de la UB
Universidad de Barcelona
Lancet Haematology, 8, 5, pp. E355-E364
The Lancet Haematology, 2021, 8 (5), pp.e355-e364. ⟨10.1016/S2352-3026(21)00060-0⟩
The Lancet Haematology, Elsevier, 2021, 8 (5), pp.e355-e364. ⟨10.1016/S2352-3026(21)00060-0⟩
Lancet Haematology, 8, E355-E364
Dipòsit Digital de la UB
Universidad de Barcelona
Lancet Haematology, 8, 5, pp. E355-E364
Summary Background Chimeric antigen receptor (CAR) T-cell therapy can induce side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), which often require intensive care unit admission. The aim